{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-039049","form_type":"8-K","ticker":"BDSX","cik":"0001439725","company_name":"BIODESIX INC","filed_at":"2023-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.931493+00:00","generated_at":"2026-06-12T04:03:30.170015+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Biodesix Q2 core lung diagnostics revenue up 58% YoY to $11.4M; raises $27.5M","bullets":["Core lung diagnostic revenue $11.4M (+58% YoY, +33% QoQ); gross margin 73% vs 64% in Q2 2022.","Net loss $13.4M improved 16% YoY; cash burn reduced 56% QoQ to $7.9M.","Raised $27.5M in private placement post-quarter from largest shareholders, board, and management.","Reaffirmed FY2023 total revenue guidance of $52-55M.","Achieved primary endpoint of ORACLE study: 74% reduction in unnecessary procedures using Nodify XL2."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-039049","json":"https://secwatch.observer/filing/0000950170-23-039049.json","markdown":"https://secwatch.observer/filing/0000950170-23-039049.md","text":"https://secwatch.observer/filing/0000950170-23-039049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439725/000095017023039049/0000950170-23-039049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439725/000095017023039049/bdsx-20230807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T04:03:30.170015+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b9fcf9d43118499a122d6a049c9fef8e70506f39","claim":"BIODESIX INC updated its second quarter ended June 30, 2023 guidance (reaffirmed).","evidence_excerpt":"On August 7, 2023, Biodesix, Inc. (the Company) issued a press release announcing the financial and operating results of the Company for the second quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1439725/000095017023039049/0000950170-23-039049-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}